Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy

New England Journal of Medicine

Volumn 350, Issue 21, 2004, Pages 2151-2158

  Kadish, Alan ^a,i   Dyer, Alan ^a   Daubert, James P ^b   Quigg, Rebecca ^a   Estes, N A Mark ^c   Anderson, Kelley P ^d   Calkins, Hugh ^e   Hoch, David ^f   Goldberger, Jeffrey ^a   Shalaby, Alaa ^h   Sanders, William E ^g   Schaechter, Andi ^a   Levine, Joseph H ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MARSHFIELD CLINIC   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f ST FRANCIS HOSPITAL   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Veteran's Affairs Pittsburgh Health System   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NITRATE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART TAMPONADE; HEMATOTHORAX; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONISCHEMIC DILATED CARDIOMYOPATHY; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SAFETY; SUDDEN DEATH; TREATMENT OUTCOME; VEIN THROMBOSIS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARRHYTHMIA; CARDIOMYOPATHY, DILATED; COMBINED MODALITY THERAPY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 2442572117     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa033088     Document Type: Article

References (31)

1. Carson PA, O'Connor CM, Miller AB, et al. Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. J Am Coll Cardiol 2000;36:541-6.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
5. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90. [Erratum, N Engl J Med 2000;342:1300.]
6. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90. [Erratum, N Engl J Med 2000;342:1300.]
7. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
9. Levine JH, Waller T, Hoch D, Greenberg S, Goldberger J, Kadish A. Implantable cardioverter defibrillator: use in patients with no symptoms and at high risk. Am Heart J 1996;131:59-65.
10. Kadish A, Quigg R, Schaechter A, Anderson KP, Estes M, Levine J. Defibrillators in nonischemic cardiomyopathy treatment evaluation. Pacing Clin Electrophysiol 2000;23:338-43.
11. Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika 1987;74:149-54.
12. Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1990;46:81-92.
13. Kim K, Demets DL. Sample size determination for group sequential clinical trials with immediate response. Stat Med 1992;11:1391-9.
14. Whitehead J, Stratton I. Group sequential trials with triangular continuation regions. Biometrics 1983;39:227-36.
15. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death. Circulation 1996;94:3198-203.
16. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
17. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
18. Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ Jr. Classification of death in and antiarrhythmia trials. J Am Coll Cardiol 1996;27:433-42.
19. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:321.
20. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
21. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
22. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002;39:780-7.
23. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heat failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
24. Rankovic V, Karha J, Passman R, Kadish AH, Goldberger JJ. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:1072-6.
25. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
26. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 2003;41:1707-12.
27. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
28. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
29. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. [Erratum, N Engl J Med 2003;348:2271.]
30. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. [Erratum, N Engl J Med 2003;348:2271.]
31. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heat failure. N Engl J Med 1999;341:709-17.